Publications

• Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
  Collins, S. E., Grant, P. M., & Shafer, R. W. (2016). Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. DRUGS, 76(1), 75-98.
• Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma.
  Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., & Pinsky, B. A. (2015). Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma. American journal of tropical medicine and hygiene, 93(2), 238-240.
• Case Report: Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid versus Serum or Plasma
  Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., & Pinsky, B. A. (2015). Case Report: Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid versus Serum or Plasma. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93(2), 238-240.
• Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients Grant, P. M., Sheikh, V., DerSimonian, R., Rupert, A., Roby, G., & Sereti, I. (2015). Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients. AIDS RESEARCH AND HUMAN RETROVIRUSES, 31(7), 739-744.
  
• Patterns of peripheral neuropathy in ART-na < ve patients initiating modern ART regimen Lee, A. J., Bosch, R. J., Evans, S. R., Wu, K., Harrison, T., & Clifford, D. B. (2015). Patterns of peripheral neuropathy in ART-na < ve patients initiating modern ART regimen. JOURNAL OF NEUROVIROLOGY, 21(2), 210-218.
  
• Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults Grant, P. M., Kitch, D., McComsey, G. A., Tierney, C., Ha, B., & Brown, T. T. (2015). Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV CLINICAL TRIALS, 16(2), 66-71.
  
• Encephalitis Caused by Chikungunya Virus in a Traveler from the Kingdom of Tonga Nelson, J., Waggoner, J. J., Sahoo, M. K., Grant, P. M., & Pinsky, B. A. (2014). Encephalitis Caused by Chikungunya Virus in a Traveler from the Kingdom of Tonga. JOURNAL OF CLINICAL MICROBIOLOGY, 52(9), 3459-3461.
  
• Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults Liang, E. C., Sceats, L., Bayless, N. L., Strauss-Albee, D. M., Kubo, J., & Blish, C. A. (2014). Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults. JOURNAL OF VIROLOGY, 88(15), 8629-8639.
  
• Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164 Grant, P. M., Komarow, L., Sanchez, A., Sattler, F. R., Asmuth, D. M., & Zolopal, A. R. (2014). Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164. HIV CLINICAL TRIALS, 15(4), 133-139.
  
• Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC MEDICINE, 12.
  
• Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations Richardson, E. T., Grant, P. M., & Zolopa, A. R. (2014). Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations. ANTIVIRAL RESEARCH, 103, 88-93.
  
• Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC medicine, 12, 46-?.
  
• TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY Talbot, A., Uwihoreye, C., Kamen, C., Grant, P., McGlynn, L., & Zolopa, A. (2013). TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY. AIDS EDUCATION AND PREVENTION, 25(6), 468-479.
  
• Low Baseline CD4(+) Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation Grant, P. M., Kitch, D., McComsey, G. A., Dube, M. P., Haubrich, R., & Brown, T. T. (2013). Low Baseline CD4(+) Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. CLINICAL INFECTIOUS DISEASES, 57(10), 1483-1488.
  
• Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202 Grant, P. M., Tierney, C., Budhathoki, C., Daar, E. S., Sax, P. E., & Katzenstein, D. (2013). Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202. HIV CLINICAL TRIALS, 14(6), 284-291.
  
• Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164 Grant, P. M., Komarow, L., Lederman, M. M., Pahwa, S., Zolopa, A. R., & Sereti, I. (2012). Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164. JOURNAL OF INFECTIOUS DISEASES, 206(11), 1715-1723.
  
• When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now! Grant, P. M., & Zolopa, A. R. (2012). When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!. Current HIV/AIDS reports, 9(3), 251-258.
  
• Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia Sax, P. E., Komarow, L., Finkelman, M. A., Grant, P. M., Andersen, J., & Zolopa, A. R. (2011). Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia. CLINICAL INFECTIOUS DISEASES, 53(2), 197-202.
  
• Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis Bendavid, E., Grant, P., Talbot, A., Owens, D. K., & Zolopa, A. (2011). Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS, 25(2), 211-220.
  
• Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis Grant, P. M., Aberg, J. A., & Zolopa, A. R. (2010). Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis. CLINICAL INFECTIOUS DISEASES, 51(8), 984-985.
  
• Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164 Sax, P. E., Sloan, C. E., Schackman, B. R., Grant, P. M., Rong, J., & Freedberg, K. A. (2010). Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. HIV CLINICAL TRIALS, 11(5), 248-259.
  
• Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance Grant, P. M., & Zolopa, A. R. (2010). Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 11(8), 901-910.
  
• Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection Grant, P. M., Komarow, L., Andersen, J., Sereti, I., Pahwa, S., & Zolopa, A. (2010). Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. PLOS ONE, 5(7).
  
• Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors Talbot, A., Grant, P., Taylor, J., Baril, J.-G., Liu, T. F., & Zolopa, A. (2010). Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2473-2479.
  
• International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase Grant, P. M., Taylor, J., Nevins, A. B., Calvez, V., Marcelin, A.-G., & Zolopa, A. R. (2010). International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(4), 1520-1525.
  
• Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life Grant, P. M., Palmer, S., Bendavid, E., Talbot, A., Slamowitz, D. C., & Zolopa, A. R. (2009). Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. JOURNAL OF CLINICAL VIROLOGY, 46(4), 305-308.
  
• The use of resistance testing in the management of HIV-1-infected patients Grant, P. M., & Zolopa, A. R. (2009). The use of resistance testing in the management of HIV-1-infected patients. CURRENT OPINION IN HIV AND AIDS, 4(6), 474-480.
  
• Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Grant, P., & Zolopa, A. (2009). Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Current HIV/AIDS reports, 6(2), 63-67.
  
• Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor Grant, P., Taylor, J., Cain, P., Short, W., Gallant, J., & Zolopa, A. (2009). Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. CLINICAL INFECTIOUS DISEASES, 48(5), 680-682.
  
• Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores Grant, P., Wong, E. C., Rode, R., Shafer, R., De Luca, A., & Zolopa, A. (2008). Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4050-4056.
  
• Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Grant, P., & Zolopa, A. (2008). Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Journal of HIV therapy, 13(2), 36-39.